RCSB PDB - 4RYC: RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]amino}pyrrolidin-3-yl]methyl}-N-(propan-2-yl)benzamide INHIBITOR

trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.

Lorthiois, E., Cumin, F., Ehrhardt, C., Kosaka, T., Sellner, H., Ostermann, N., Francotte, E., Wagner, T., Maibaum, J.

(2015) Bioorg Med Chem Lett 25: 1782-1786

• PubMed: 25782742 Search on PubMed
• DOI: https://doi.org/10.1016/j.bmcl.2015.02.039


• PubMed Abstract: 

  Recently, we reported on the discovery of (3S,4S)-disubstituted pyrrolidines (e.g., 2) as inhibitors of the human aspartyl protease renin. In our effort to further expand the scope of this novel class of direct renin inhibitors, a new sub-series was designed in which the prime site substituents are linked to the pyrrolidine core by a (3S)-amino functional group. In particular, analogs bearing the corresponding sulfonamide spacer (50, 51 and 54a) demonstrated a pronounced increase in in vitro potency compared to compound 2.

---

Organizational Affiliation: 

Novartis Pharma AG, Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland. Electronic address: edwige.lorthiois@novartis.com.